Nal-anti-TIGIT bifunctional antibody drug conjugate - TuHURA Biosciences Nal-anti-TIGIT bifunctional antibody drug conjugate
Alternative Names: Nal-Anti TIGIT; TBS-2025Latest Information Update: 07 Feb 2025
At a glance
- Originator TuHURA Biosciences
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Opioid delta receptor antagonists; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Myelodysplastic syndromes
Most Recent Events
- 01 Aug 2024 Preclinical trials in Myelodysplastic syndromes in USA (Parenteral) (TuHURA Biosciences pipeline, August 2024)